Close Menu

MD Anderson

A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.

The study will evaluate the effects of investigational drug IN10018 as a monotherapy and in combination with a MEK inhibitor.

Researchers showed that detectable ctDNA following chemoradiation may identify lung cancer patients who will likely have disease recurrence and should receive consolidation immunotherapy.

The analysis also suggested ways to outwit these mechanisms based on the degree of immune cell infiltration into the tumor. 

Researchers performed single-cell RNA sequencing and demonstrated that the emerging heterogeneity in SCLC necessitates optimal combination treatment strategies at the outset.  

Mutated KRAS protein has been notoriously difficult to target with drugs, but MD Anderson researchers are trying to get at KRAS mRNA using exosomes.

Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.

The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.

Treatment biomarkers for small cell lung cancer have been nearly non-existent, but researchers are beginning to find ones that mark PARP inhibitor response.

Pfizer expects its own trial of talazoparib for this new indication to wrap up in 2021, ideally recapitulating the positive results seen in this smaller group.

Pages